<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02666885</url>
  </required_header>
  <id_info>
    <org_study_id>ZPM_Demonstrator_HNC</org_study_id>
    <nct_id>NCT02666885</nct_id>
  </id_info>
  <brief_title>Personalised Postoperative Radiochemotherapy in Patients With Head and Neck Cancer</brief_title>
  <official_title>Personalised Postoperative Radiochemotherapy in Patients With Head and Neck Cancer and Development of a Multi-parametric Decision Support System for Personalised Medicine in Radiation Oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current trial is evaluating the integration of a pretherapeutical FDG-PET/MRI in the
      adjuvant radiochemotherapy in patients with head and neck cancer. As a secondary hypothesis
      the intention is to develop of a multi-parametric decision support system for personalised
      medicine by integrating functional imaging, γH2AX-analysis and genetic information.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>locoregional progression free survival</measure>
    <time_frame>2 years after primary diagnosis</time_frame>
    <description>15% improvement in loco-regional PFS at 2 years through integrtion of pre-operative PET/MR imaging into RT treatment planning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years after primary diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years after primary diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of a multi-parametric decision support system</measure>
    <time_frame>after termination of recruitment and follow up up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Integration of PET/MRI in radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Integration of pretherapeutical PET/MRI in adjuvant radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Integration of PET/MRI in radiotherapy</intervention_name>
    <description>Integration of pretherapeutical PET/MRI in adjuvant radiotherapy</description>
    <arm_group_label>Integration of PET/MRI in radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  locally-advanced HNSCC (Oro- and Hypopharynx) stage III and IV without distant
             metastases

          -  no contraindications for PET/MRI

          -  no contraindications for radiochemotherapy

          -  informed consent

          -  ECOG PS 0/2

        Exclusion Criteria:

          -  Secondary malignancies that might influence outcome within 2 years after
             radiochemotherapy of the HNSCC

          -  previous PET/CT

          -  induction therapy

          -  pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Zips, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen, Department of Radiation Oncology, Tuebingen, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Zips, MD, Prof</last_name>
    <phone>+49 7071 29</phone>
    <phone_ext>82165</phone_ext>
    <email>roinfo@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silke Theden</last_name>
    <phone>+49 7071 29</phone>
    <phone_ext>83420</phone_ext>
    <email>silke.theden@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tübingen, Department of Radiation Oncology</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Zips, MD, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Personalized Medicine</keyword>
  <keyword>Radiation Oncology</keyword>
  <keyword>Functional Imaging</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Decision Support System</keyword>
  <keyword>Radiomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

